A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Investors welcomed reports that the next wave of President Trump's tariffs will be more targeted than threatened.

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

In late afternoon trading, shares of the Nashville-based eyecare pharmaceutical company (ticker: HROW) were priced at $30.01, ...

“As a critical industry, any disruption to the production or distribution of pharmaceutical products can have significant cost implications for the industry and health ramifications for the ...

Pandemic darlings had a lot in common with AI, quantum computing and 3-D printing.